The Genomic Landscape in Philadelphia-Negative Myeloproliferative Neoplasm Patients with Second Cancers

• Published in: Cancers Vol. 14; no. 14; p. 3435
• Main Authors: Hsu, Chia-Chen, Wang, Ying-Hsuan, Chen, Yi-Yang, Chen, Ying-Ju, Lu, Chang-Hsien, Wu, Yu-Ying, Yang, Yao-Ren, Tsou, Hsing-Yi, Li, Chian-Pei, Huang, Cih-En, Chen, Chih-Cheng
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 14.07.2022; MDPI
• Subjects: Cancer; Cell differentiation; Chromosomes; Cytokines; Development and progression; Embryos; Epidemiology; Epigenetics; Gene mutations; Genetic aspects; genetic predisposition; Genetic transformation; Genomes; Genomics; Granulocytes; Haplotypes; Hematology; Hematopoietic stem cells; Inflammation; Interleukin 23; Kinases; KRT6A; Leukocytes (granulocytic); Macrophages; Mutation; Myeloid cells; Myeloproliferative disorders; myeloproliferative neoplasms; Oncology, Experimental; Pathogenesis; Plasma; Plasma levels; Risk factors; second cancers; Second primary cancer; Stem cells; Tumorigenesis; whole exome sequencing; Taiwan; United States > US; myeloproliferative neoplasms; inflammation; genetic predisposition; second cancers; whole exome sequencing; KRT6A; driver mutation
• ISSN: 2072-6694; 2072-6694
• DOI: 10.3390/cancers14143435

Patients with myeloproliferative neoplasms (MPNs) are characterized by systemic inflammation. With the indolent nature of the diseases, second cancers (SCs) have emerged as a challenging issue in afflicted patients. Epidemiological studies have confirmed the excessive risk of SCs in MPNs, but little is known about their molecular basis. To explore further, we used whole exome sequencing to explore the genetic changes in the granulocytes of 26 paired MPN patients with or without SC. We noticed that MPN−SC patients harbor genomic variants of distinct genes, among which a unique pattern of co-occurrence or mutual exclusiveness could be identified. We also found that mutated genes in MPN−SC samples were enriched in immune-related pathways and inflammatory networks, an observation further supported by their increased plasma levels of TGF-β and IL-23. Noteworthily, variants of KRT6A, a gene capable of mediating tumor-associate macrophage activity, were more commonly detected in MPN−SC patients. Analysis through OncodriveCLUST disclosed that KRT6A replaces JAK2V617F as the more prominent disease driver in MPN−SC, whereas a major mutation in this gene (KRT6A c.745T>C) in our patients is linked to human carcinoma and predicted to be pathogenic in COSMIC database. Overall, we demonstrate that inflammation could be indispensable in MPN−SC pathogenesis.